Vai al contenuto principale della pagina

Drug safety: FDA's future inspection plans need to address issues presented by COVID-19 backlog : testimony before the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, Committee on Appropriations, House of Representatives / / statement of Mary Denigan-Macauley



(Visualizza in formato marc)    (Visualizza in BIBFRAME)

Titolo: Drug safety: FDA's future inspection plans need to address issues presented by COVID-19 backlog : testimony before the Subcommittee on Agriculture, Rural Development, Food and Drug Administration, and Related Agencies, Committee on Appropriations, House of Representatives / / statement of Mary Denigan-Macauley Visualizza cluster
Pubblicazione: [Washington, D.C.] : , : United States Government Accountability Office, , 2021
Descrizione fisica: 1 online resource (18 pages) : color illustrations, color map
Soggetto topico: COVID-19 (Disease) - Treatment - United States
COVID-19 Pandemic, 2020- - United States
Drugs - Inspection - United States
Drugs - United States - Safety measures
Drug reimportation - United States
Persona (resp. second.): Denigan-MacauleyMary
Note generali: "For release on delivery, expected at 10:00 a.m. ET, Thursday, March 4, 2021."
Nota di bibliografia: Includes bibliographical references.
Altri titoli varianti: Drug safety
Titolo autorizzato: Drug safety: FDA's future inspection plans need to address issues presented by COVID-19 backlog  Visualizza cluster
Formato: Materiale a stampa
Livello bibliografico Monografia
Lingua di pubblicazione: Inglese
Record Nr.: 9910715327503321
Lo trovi qui: Univ. Federico II
Opac: Controlla la disponibilità qui